4.1 Review

Epigenetic mechanisms of facioscapulohumeral muscular dystrophy

出版社

ELSEVIER SCIENCE BV
DOI: 10.1016/j.mrfmmm.2008.07.011

关键词

FSHD; Muscular dystrophy; D4Z4 repeat; Epigenetics; Chromatin; Nuclear organization

资金

  1. Netherlands Organization for Scientific Research
  2. Muscular Dystrophy Association USA
  3. FSH Society
  4. National Institutes of Health and the Fields Center for FSHD & Neuromuscular Research

向作者/读者索取更多资源

Facioscapulohumeral muscular dystrophy (FSHD) seems to be caused by a complex epigenetic disease mechanism as a result of contraction of the polymorphic macrosatellite repeat D4Z4 on chromosome 4qter. Currently, the exact mechanism causing the FSHD phenotype is still not elucidated. In this review, we discuss the genetic and epigenetic changes observed in patients with FSHD and the possible disease mechanisms that may be associated with FSHD pathogenesis. (c) 2008 Elsevier B.V. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.1
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Genetics & Heredity

Chromosome 10q-linked FSHD identifies DUX4 as principal disease gene

Richard J. L. F. Lemmers, Patrick J. van der Vliet, Ana Blatnik, Judit Balog, Janez Zidar, Don Henderson, Rianne Goselink, Stephen J. Tapscott, Nicol C. Voermans, Rabi Tawil, George W. A. M. Padberg, Baziel G. M. van Engelen, Silvere M. van der Maarel

Summary: This study identified two FSHD families in which the disease is caused by a de novo D4Z4 repeat exchange between chromosomes 4 and 10, leading to repeat contraction and DUX4 expression from chromosome 10. The genetic lesion causal to FSHD in these families is physically separated from other candidate genes on chromosome 4. Muscle cell cultures from affected family members exhibited the characteristic molecular features of FSHD, indicating that DUX4 derepression is the dominant disease pathway for FSHD.

JOURNAL OF MEDICAL GENETICS (2022)

Article Biochemistry & Molecular Biology

Elevated plasma complement components in facioscapulohumeral dystrophy

Chao-Jen Wong, Leo Wang, V. Michael Holers, Ashley Frazer-Abel, Silvere M. van der Maarel, Rabi Tawil, Jeffrey M. Statland, Stephen J. Tapscott

Summary: Advances in understanding the pathophysiology of facioscapulohumeral dystrophy (FSHD) have led to the development of therapeutic approaches and the need for biomarkers of disease activity and progression. This study found elevated complement components in plasma from FSHD patients, suggesting the potential use of complement activation measurements as a non-invasive assessment of FSHD disease activity, progression, and response to therapies.

HUMAN MOLECULAR GENETICS (2022)

Article Biochemistry & Molecular Biology

High-resolution breakpoint junction mapping of proximally extended D4Z4 deletions in FSHD1 reveals evidence for a founder effect

Richard J. L. F. Lemmers, Patrick J. van der Vliet, David San Leon Granado, Nienke van der Stoep, Henk Buermans, Robin van Schendel, Joost Schimmel, Marianne de Visser, Rudy van Coster, Marc Jeanpierre, Pascal Laforet, Meena Upadhyaya, Baziel van Engelen, Sabrina Sacconi, Rabi Tawil, Nicol C. Voermans, Mark Rogers, Silvere M. van der Maarel

Summary: Facioscapulohumeral muscular dystrophy (FSHD) is a genetic muscle disease that can be diagnosed by analyzing the D4Z4 repeat on chromosome 4, but atypical rearrangement may affect the accuracy of diagnosis. Research shows that some DPED alleles are derived from an ancient founder allele, and the deletion of genetic elements in some DPED alleles may require reassessment of their role in the pathogenesis of the disease.

HUMAN MOLECULAR GENETICS (2022)

Editorial Material Clinical Neurology

259th ENMC international workshop: Anaesthesia and neuromuscular disorders 11 December, 2020 and 28-29 May, 2021

L. R. van den Bersselaar, S. Riazi, M. M. J. Snoeck, H. Jungbluth, N. C. Voermans

NEUROMUSCULAR DISORDERS (2022)

Article Multidisciplinary Sciences

Facioscapulohumeral dystrophy transcriptome signatures correlate with different stages of disease and are marked by different MRI biomarkers

Anita van den Heuvel, Saskia Lassche, Karlien Mul, Anna Greco, David San Leon Granado, Arend Heerschap, Benno Kusters, Stephen J. Tapscott, Nicol C. Voermans, Baziel G. M. van Engelen, Silvere M. van der Maarel

Summary: This study investigates FSHD-associated transcriptome signatures in FSHD skeletal muscle biopsies and explores their correlation with various disease-associated factors. It also analyzes the predictive power of imaging-based biomarkers for detecting FSHD signatures in clinical trials. Additionally, the study examines the role of infiltrating non-muscle cell types in FSHD signature expression.

SCIENTIFIC REPORTS (2022)

Review Cell Biology

Meeting report: the 2021 FSHD International Research Congress

Sujatha Jagannathan, Jessica C. de Greef, Lawrence J. Hayward, Kyoko Yokomori, Davide Gabellini, Karlien Mul, Sabrina Sacconi, Jamshid Arjomand, June Kinoshita, Scott Q. Harper

Summary: Facioscapulohumeral muscular dystrophy (FSHD) is a common genetic myopathy characterized by progressive muscle wasting. The recent FSHD International Research Congress provided a platform for researchers and clinicians to share the latest advances in understanding the disease mechanisms and discuss therapeutic strategies and clinical outcome measures.

SKELETAL MUSCLE (2022)

Article Clinical Neurology

Diagnostic capabilities of nanopore long-read sequencing in muscular dystrophy

Christine C. Bruels, Hannah R. Littel, Audrey L. Daugherty, Seth Stafki, Elicia A. Estrella, Emily S. McGaughy, Don Truong, Jonathan P. Badalamenti, Lynn Pais, Vijay S. Ganesh, Anne O'Donnell-Luria, Heather J. Stalker, Yang Wang, Christin Collins, Andrea Behlmann, Richard J. L. F. Lemmers, Silvere M. van der Maarel, Regina Laine, Partha S. Ghosh, Basil T. Darras, Carla D. Zingariello, Christina A. Pacak, Louis M. Kunkel, Peter B. Kang

Summary: Many individuals with muscular dystrophies remain genetically undiagnosed despite clinical testing. This study found that nanopore genomic long-read sequencing can help identify previously undetected pathogenic variants, streamlining genetic diagnostic approaches for muscular dystrophy.

ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2022)

Review Clinical Neurology

Facioscapulohumeral muscular dystrophy: the road to targeted therapies

Mara S. S. Tihaya, Karlien Mul, Judit Balog, Jessica C. C. de Greef, Stephen J. J. Tapscott, Rabi Tawil, Jeffrey M. M. Statland, Silvere M. van der Maarel

Summary: Advances in the molecular understanding of FSHD have revealed the epigenetic de-repression of the DUX4 gene in skeletal muscle as the cause of the disease. This has led to the identification of potential targeted therapies and improved understanding of the disease mechanism. The development of disease modifying treatments, ongoing clinical trials, and specific outcome measures and assessment tools for FSHD are discussed in this review.

NATURE REVIEWS NEUROLOGY (2023)

Article Cell Biology

USP18 is an essential regulator of muscle cell differentiation and maturation

Cyriel Sebastiaan Olie, Adan Pinto-Fernandez, Andreas Damianou, Iolanda Vendrell, Hailiang Mei, Bianca den Hamer, Erik van der Wal, Jessica C. de Greef, Vered Raz, Benedikt M. Kessler

Summary: The ubiquitin proteasomal system plays a critical role in muscle physiology, but the function of deubiquitinating enzymes (DUBs) in muscle cells remains poorly understood. Through a genetic screen, we discovered that the depletion of USP18, a DUB, affects muscle cell differentiation. USP18 regulates differentiation initiation and maintenance independently of ISG15 and the ISG response. Alterations in gene networks and protein expression profiles were observed in the absence of USP18, leading to disrupted calcium homeostasis and reduced contractile force.

CELL DEATH & DISEASE (2023)

Article Biology

SMCHD1 and LRIF1 converge at the FSHD-associated D4Z4 repeat and LRIF1 promoter yet display different modes of action

Darina Sikrova, Alessandra M. Testa, Iris Willemsen, Anita van den Heuvel, Stephen J. Tapscott, Lucia Daxinger, Judit Balog, Silvere M. van der Maarel

Summary: Facioscapulohumeral muscular dystrophy (FSHD) is caused by the derepression of the 4q-linked D4Z4 macrosatellite repeat, leading to inappropriate expression of the D4Z4 repeat-encoded DUX4 gene in skeletal muscle. Germline mutations in chromatin modifiers SMCHD1 and LRIF1 can result in D4Z4 chromatin relaxation. Alternative modes of repression of D4Z4 by SMCHD1 and LRIF1 are identified, providing insights into the understanding of FSHD.

COMMUNICATIONS BIOLOGY (2023)

Meeting Abstract Clinical Neurology

FUNCTIONAL MONOVALENCY AMPLIFIES THE PATHOGENICITY OF ANTI-MUSK IGG4 IN MYASTHENIA GRAVIS

Dana L. E. Vergoossen, Jaap J. Plomp, Christoph J. Gstottner, Yvonne E. Fillie-Grijpma, Roy Augustinus, Robyn L. K. Verpalen, Manfred Wuhrer, Paul W. H. I. Parren, Elena Dominguez-Vega, Silvere M. van der Maarel, Jan J. G. M. Verschuuren, Maartje G. Huijbers

MUSCLE & NERVE (2022)

Meeting Abstract Clinical Neurology

IGG4-MEDIATED AUTOIMMUNE DISEASES HAVE A NORMAL B CELL COMPARTMENT

Laurent M. Paardekooper, Yvonne E. Fillie-Grijpma, Alita J. van der Sluijs-Gelling, Mihaela Zlei, Remco van Doorn, Maarten H. Vermeer, Manuela Paunovic, Maarten J. Titulaer, Silvere M. van der Maarel, Jacques J. M. van Dongen, Jan J. Verschuuren, Maartje G. Huijbers

MUSCLE & NERVE (2022)

Meeting Abstract Immunology

IgG4-mediated autoimmune diseases have a normal (IgG4) B cell compartment

Laurent M. Paardekooper, Yvonne E. Fillie Grijpma, Alita J. Van der Sluijs Gelling, Mihaela Zlei, Remco Van Doorn, Maarten H. Vermeer, Silvere M. Van der Maarel, Jacques J. M. Van Dongen, Jan J. Verschuuren, Maartje G. Huijbers

EUROPEAN JOURNAL OF IMMUNOLOGY (2021)

Meeting Abstract Immunology

Functional monovalency of IgG4 autoantibodies amplifies their pathogenicity in MuSK myasthenia gravis

Dana L. Vergoossen, Jaap J. Plomp, Christoph Gstottner, Yvonne E. Fillie Grijpma, Roy Augustinus, Robyn Verpalen, Manfred Wuhrer, Paul W. Parren, Elena Dominguez Vega, Silvere M. Van der Maarel, Jan J. Verschuuren, Maartje G. Huijbers

EUROPEAN JOURNAL OF IMMUNOLOGY (2021)

Article Biotechnology & Applied Microbiology

The accurate bypass of pyrimidine dimers by DNA polymerase eta contributes to ultraviolet-induced mutagenesis

C. F. M. Menck, R. S. Galhardo, A. Quinet

Summary: Studies have shown that xeroderma pigmentosum variant (XP-V) patients have mutations in the POLH gene, resulting in a high frequency of skin tumors. However, it is paradoxical that the translesion synthesis DNA polymerase eta (Pol η) in these patients can actually suppress mutations, and the mechanism behind this is still unclear. Recent evidence suggests that cyclobutane pyrimidine dimers (CPDs) play an instructional role for Pol η, enabling accurate replication of these lesions, and the mutagenic effects induced by UV radiation are caused by the deamination of C-containing CPDs. This process leads to C>T transitions, which are the most common mutations in skin cancers. The delayed replication in XP-V cells amplifies the deamination of C in CPDs and increases the burden of C>T mutations through the activity of backup TLS polymerases.

MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS (2024)